Challenges and Enablers for Smartphone Use by Persons With Vision Loss During the COVID-19 Pandemic: A Report of Two Case Studies.

Purpose: Studies have reported that knowledge and skills to operate smartphones among people with profound visual loss are limited especially in low- to middle-income countries as many important functions of smartphones are unknown to them. This report presents smartphone use, its challenges, and enablers in two persons with profound visual impairment while executing their daily routine and instrumental living activities amidst the COVID-19 pandemic.

Case Selection And Interview: During the lockdown period, we provided tele (vision) rehabilitation service.

Coronavirus Disease 2019-Related Health Disparities in Ophthalmology with a Retrospective Analysis at a Large Academic Public Hospital.

The coronavirus disease 2019 pandemic has disproportionately affected racial and ethnic minorities in the United States. Although recent meta-analyses have identified the prevalence of ocular manifestations in severe acute respiratory syndrome coronavirus 2 infection, no studies with these potential findings have been implemented in examining ophthalmic disparities in racial and ethnic minorities. It is additionally clear that patient access to eye care from coronavirus disease 2019 has been disproportionate in underserved communities.

U.S. Associated Pacific Islands Health Care Teams Chart a Course for Improved Health Systems: Implementation and Evaluation of a Non-communicable Disease Collaborative Model.

The burden of non-communicable disease (NCD) is increasing in the U.S. Associated Pacific Islands (USAPI).

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.

Aim: To investigate the impact of KRAS mutation variants on the activity of regorafenib in SW48 colorectal cancer cells.

Materials & Methods: Activity of regorafenib was evaluated in isogenic SW48 KRAS wild-type (WT) and mutant cells. Subcutaneous xenografts (KRAS WT and G12C mutant variants) in NOD/SCID mice were analyzed to elucidate the effect of regorafenib treatment in vivo.